StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

Earnings

AbbVie's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 3, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$16.99B
+10.2% on a year earlier
Adjusted diluted EPS, Q2 FY2026
$3.65
$2.97 a year earlier
Latest guidance
Lowered
Oct 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of AbbVie's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 3, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 30, 2026before the open––––Release
Q2 FY2026ended Jun 30, 2026Jul 31, 2026before the open$16.99B+10.2%$2.03$3.65Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026before the open$15.00B+12.4%$0.39$2.65Release
Q4 FY2025ended Dec 31, 2025Feb 4, 2026before the open$16.62B+10.0%$1.02$2.71Release
Q3 FY2025ended Sep 30, 2025Oct 31, 2025before the open$15.78B+9.1%$0.10$1.86Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$15.42B+6.6%$0.52$2.97Release
Q1 FY2025ended Mar 31, 2025Apr 25, 2025before the open$13.34B+8.4%$0.72$2.46Release
Q4 FY2024ended Dec 31, 2024Jan 31, 2025before the open$15.10B+5.6%-$0.02$2.16Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$14.46B+3.8%$0.88$3.00Release
Q2 FY2024ended Jun 30, 2024Jul 25, 2024before the open$14.46B+4.3%$0.77$2.65Release
Q1 FY2024ended Mar 31, 2024Apr 26, 2024before the open$12.31B+0.7%$0.77$2.31Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

AbbVie's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Adjusted Diluted EPSnon-GAAPQ3 FY2026$3.73 – $3.77–NewOct 5, 2026
Adjusted Diluted EPSnon-GAAPFY2026$13.76 – $13.96$13.87 – $14.07LoweredOct 5, 2026
Adjusted Diluted EPSnon-GAAPFY2026$13.91 – $14.11$13.96 – $14.16LoweredJul 6, 2026

Guidance vs results

The last range AbbVie gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q2 FY2026Adjusted Diluted EPS$3.57 – $3.61$3.65Above range
Q1 FY2026Adjusted Diluted EPS Range$2.56 – $2.60$2.65Above range
FY2025Adjusted Diluted EPS Range$9.90 – $9.94$10.00Σ4QAbove range
Q4 FY2025Adjusted Diluted EPS Range$2.61 – $2.65$2.71Above range
Q3 FY2025Adjusted Diluted EPS Range$1.74 – $1.78$1.86Above range
Q1 FY2025Adjusted Diluted EPS$2.34 – $2.38$2.46Above range
Q4 FY2024Adjusted Diluted EPS Range$2.06 – $2.10$2.16Above range

Guidance history

Every forecast AbbVie put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 5, 2026Adjusted Diluted EPSQ3 FY2026$3.73 – $3.77New
Oct 5, 2026Adjusted Diluted EPSFY2026$13.76 – $13.96Lowered
Jul 31, 2026adjusted diluted EPSFY2026$13.87 – $14.07Lowered
Jul 6, 2026Adjusted Diluted EPSFY2026$13.91 – $14.11Lowered
Jul 6, 2026Adjusted Diluted EPSQ2 FY2026$3.57 – $3.61New
Apr 29, 2026adjusted diluted EPSFY2026$14.08 – $14.28Lowered
Apr 3, 2026Adjusted Diluted EPS RangeFY2026$13.96 – $14.16New
Apr 3, 2026Adjusted Diluted EPS RangeQ1 FY2026$2.56 – $2.60New
Feb 4, 2026adjusted diluted EPSFY2026$14.37 – $14.57New
Jan 7, 2026Adjusted Diluted EPS RangeFY2025$9.90 – $9.94Lowered
Jan 7, 2026Adjusted Diluted EPS RangeQ4 FY2025$2.61 – $2.65New
Oct 31, 2025adjusted diluted EPSFY2025$10.61 – $10.65Lowered
Oct 3, 2025Adjusted Diluted EPS RangeFY2025$10.38 – $10.58New
Oct 3, 2025Adjusted Diluted EPS RangeQ3 FY2025$1.74 – $1.78New
Jul 31, 2025adjusted diluted EPSFY2025$11.88 – $12.08Lowered
Apr 25, 2025adjusted diluted EPSFY2025$12.09 – $12.29Raised
Apr 3, 2025Adjusted Diluted EPSFY2025$11.99 – $12.19Lowered
Apr 3, 2025Adjusted Diluted EPSQ1 FY2025$2.34 – $2.38New
Jan 31, 2025adjusted diluted EPSFY2025$12.12 – $12.32New
Jan 6, 2025Adjusted Diluted EPS RangeFY2024$10.02 – $10.06Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AbbVie filed with the SEC as exhibits to Form 8-K or 6-K

  1. AbbVie Reports Third-Quarter 2026 Financial Results
    Results
  2. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results
  3. AbbVie Completes Acquisition of Apogee Therapeutics
    Update
  4. AbbVie Reports Second-Quarter 2026 Financial Results
    Results
  5. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results
  6. to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
    Update
  7. 8-K exhibit EX-99.2
    Update
  8. AbbVie Reports First-Quarter 2026 Financial Results
    Results
  9. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results
  10. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
    Results
  11. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results
  12. AbbVie Reports Third-Quarter 2025 Financial Results
    Results
  13. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results
  14. AbbVie Reports Second-Quarter 2025 Financial Results
    Results
  15. Guidance Including the Impact of Acquired IPR&D and Milestones Expense
    Results